New research has revealed how malaria parasites cause an inflammatory reaction that sabotages our body's ability to protect itself against the disease.
Can the emergence of antibiotic-resistant bacteria be squarely blamed on the misuse and overuse of antibiotics? No, there is more to the problem than the misuse of common medications, says a University of Georgia researcher.
Merck, known as MSD outside the United States and Canada, announced that the application for Emergency Use Assessment and Listing (EUAL) for the company’s investigational Ebola Zaire vaccine, V920 (rVSV?G-ZEBOV-GP, live attenuated), has been accepted for review by the World Health Organization (WHO).
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation announced that REVLIMID® (lenalidomide), a cancer medicine that is administered orally, has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for use in combination with dexamethasone as a treatment for patients newly diagnosed with multiple myeloma. This marketing authorization expands upon the approval of REVLIMID in 2010 for the treatment of patients with relapsed or refractory multiple myeloma.
Recipharm AB, a leading contract development and manufacturing organisation in the pharmaceutical industry, has entered into the previously announced strategic collaboration with Alcon, a Novartis company, and signed a long term supply agreement whereby Recipharm will manufacture a range of ophthalmic products using Blow Fill Seal technology.
Sanofi Pasteur, the vaccines division of Sanofi, announced that the Philippines have granted marketing approval to Dengvaxia®, making it the first vaccine to be licensed for the prevention of dengue in Asia.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
